BALYASNY ASSET MANAGEMENT L.P. - ESPERION THERAPEUTICS INC NE ownership

ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.

Quarter-by-quarter ownership
BALYASNY ASSET MANAGEMENT L.P. ownership history of ESPERION THERAPEUTICS INC NE
ValueSharesWeighting
Q2 2023$22,294
-99.7%
16,039
-99.7%
0.00%
-100.0%
Q1 2023$7,586,462
-64.5%
4,771,360
+39.1%
0.02%
-67.2%
Q4 2022$21,363,523
+300.7%
3,429,137
+331.0%
0.06%
+262.5%
Q3 2022$5,331,000
+6914.5%
795,671
+6546.7%
0.02%
Q2 2022$76,000
-98.0%
11,971
-88.0%
0.00%
-100.0%
Q3 2020$3,717,000
+16.3%
100,000
+60.6%
0.03%
-3.6%
Q2 2020$3,196,000
-67.5%
62,282
-80.0%
0.03%
-76.1%
Q1 2020$9,830,000
-56.1%
311,738
-17.0%
0.12%
-12.0%
Q4 2019$22,384,000
+351.5%
375,377
+177.6%
0.13%
+291.2%
Q3 2019$4,958,000
-34.0%
135,230
-16.2%
0.03%
-29.2%
Q2 2019$7,511,000
+51.2%
161,448
+49.5%
0.05%
+33.3%
Q4 2018$4,968,000
+1031.7%
108,000
+991.6%
0.04%
+1700.0%
Q3 2018$439,000
-72.8%
9,894
-76.0%
0.00%
-71.4%
Q2 2018$1,616,000
-85.1%
41,224
-72.6%
0.01%
-84.4%
Q1 2018$10,881,000
-59.0%
150,441
-62.7%
0.04%
-45.8%
Q4 2017$26,544,000
+34.7%
403,164
+2.5%
0.08%
+7.8%
Q3 2017$19,705,000
+25.1%
393,150
+15.5%
0.08%
+18.5%
Q2 2017$15,757,000
+801.4%
340,483
+587.8%
0.06%
+712.5%
Q1 2017$1,748,00049,5000.01%
Other shareholders
ESPERION THERAPEUTICS INC NE shareholders Q3 2023
NameSharesValueWeighting ↓
Meditor Group Ltd 2,679,835$69,675,00019.39%
Endurant Capital Management LP 207,293$5,390,0001.94%
Bellevue Group AG 5,138,451$133,599,0001.53%
Rhenman & Partners Asset Management AB 592,225$15,398,0001.26%
PLATINUM INVESTMENT MANAGEMENT LTD 1,562,869$40,635,0000.93%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 31,434$817,0000.62%
WASATCH ADVISORS LP 3,998,010$103,949,0000.51%
HAMILTON LANE ADVISORS LLC 46,181$1,201,0000.45%
Boxer Capital, LLC 500,000$13,000,0000.42%
DCF Advisers, LLC 38,500$1,001,0000.41%
View complete list of ESPERION THERAPEUTICS INC NE shareholders